Health & Bio2 min read
Health & Bio
Novo Nordisk Halts Two Heart-Disease Trials of Anti-Inflammatory Drug Ziltivekimab
Novo Nordisk has stopped two cardiovascular trials of ziltivekimab after a data monitoring committee found them unlikely to succeed, following an earlier trial in which the drug failed to reduce heart attacks and deaths.
Step by step
- 1
ZEUS trial fails to cut heart attacks
- 2
Data committee reviews HERMES and ATHENA
- 3
Committee finds trials unlikely to succeed
- 4
Novo Nordisk halts both trials
Novo Nordisk has halted two clinical trials, named HERMES and ATHENA, of its drug ziltivekimab, which aims to reduce inflammation as a way to improve cardiovascular health. The company informed trial investigators of the decision on a Friday, after a found the trials were unlikely to succeed.
The move follows the earlier failure of ziltivekimab in the ZEUS trial, which found that although the drug lowered markers of inflammation in the body, it did not reduce the risk of major clinical complications, including deaths and heart attacks.
The halted trials are another setback for the broader strategy of using anti-inflammatory drugs to treat cardiovascular disease.
Terms explained
The story so far
- Volunteer Responders Boosted CPR Rates but Not Survival, Danish Trial Finds
- Novartis Heart Drug Pelacarsen Fails Pivotal Trial Despite Lowering Risk Marker
- Trial Finds a Cheaper Imaging Scan Works as Well for Tricky Heart Stenting
- Routine Invasive Heart Attack Treatment Still Best for Very Elderly Patients, EVAOLD Trial Finds
- Laughter Therapy Eases Breathlessness in COPD Patients About as Well as Breathing Exercises, Trial Finds
- Structured Lifestyle Coaching Boosted Brain Health 55% More Than Basic Advice
- Novo Nordisk Halts Two Heart-Disease Trials of Anti-Inflammatory Drug Ziltivekimab
#Novo Nordisk#cardiovascular disease#clinical trial#inflammation#ziltivekimab
Rate this story